~~<i id='0A43D273A4'><strike id='0A43D273A4'><tt id='0A43D273A4'><pre id='0A43D273A4'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：knowledge 2025-09-06 07:52:16 Page View：17

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Eight reasons why you should get an updated Covid vaccine
Next article： 23andMe had bad news about my health. I wish a person had delivered it

explore

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Hospitals use virtual reality to design more inclusive rooms for kids

ResearcherHaripriyaSathyanarayananobservingasapediatricparticipantexploresahospitalroominvirtualreal

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Medicare to cover more brain scans related to Alzheimer’s drugs

Illustration:AlexHogan/STAT;Photo:EisaiviaAPMedicarehasofficiallyexpandeditscoveragepolicyforbrainsc